Mergers & AcquisitionsBy The Online Investor Staff, updated Sun., Jan. 29, 5:37 PM
|This Slide: #94 of 100|
Slide #94. Calidi Biotherapeutics, Inc. — First Light Acquisition Group
Calidi Biotherapeutics, Inc.
First Light Acquisition Group (AMEX:FLAG)
Calidi Biotherapeutics, Inc. ("Calidi" or the "Company"), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, and First Light Acquisition Group ("FLAG") (NYSE American: FLAG), a special purpose acquisition company organized to acquire or merge with one or more businesses, today announced they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs. Upon closing of the transaction, anticipated to occur in the second quarter of 2023, the combined company will be named Calidi Biotherapeutics, Inc. and led by Allan Camaisa, CEO and Chairman of the Board. In addition, the combined company's common stock intends to list on the NYSE American under the ticker "CLDI."
Free FLAG Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts